ValiRx Strikes RNA Helicase Inhibitor Deal with McGill and IRICoR to Drive Asset-Level Growth

ValiRx plc ( (GB:VAL) ) has shared an update.

ValiRx has entered into a nine‑month Evaluation and Material Transfer Agreement with McGill University and IRICoR to assess a second‑generation, orally available RNA helicase inhibitor, with its subsidiary Inaphaea Biolabs responsible for establishing target engagement and potency and owning the resulting evaluation data. Under the deal, IRICoR will create a new Canadian subsidiary, NewCo, to commercialise the evaluation results and background IP, with ValiRx holding an option to license the results into NewCo for a 15% equity stake and potentially provide up to £2m in seed funding, or alternatively receive a 1.5x return on its evaluation investment if it opts out, a structure that management says supports asset‑level dilution, attracts external funding and opens multiple strategic pathways to value creation in both human and veterinary health markets.

The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.40 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.

Spark’s Take on GB:VAL Stock

According to Spark, TipRanks’ AI Analyst, GB:VAL is a Neutral.

ValiRx plc’s overall stock score is primarily impacted by its challenging financial performance, characterized by significant losses and reliance on external financing. The technical analysis suggests a bearish trend, with some potential for upward movement. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield.

To see Spark’s full report on GB:VAL stock, click here.

More about ValiRx plc

ValiRx plc is an AIM-listed life sciences company focused on early-stage cancer therapeutics and women’s health, providing scientific, financial and commercial frameworks to accelerate the translation of novel drug candidates from pre-clinical studies to clinic-ready assets. Through its subsidiary structure and collaborations with academic and research institutions, ValiRx incubates and develops promising therapies, aiming for streamlined, lower-cost drug development and ultimately out-licensing or partnering lead candidates for further clinical development and commercialisation.

Average Trading Volume: 15,630,100

Technical Sentiment Signal: Sell

Current Market Cap: £3.12M

See more data about VAL stock on TipRanks’ Stock Analysis page.